HER-2 negative breast cancer

AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
Mon, 04/16/18 - 01:21 am
AstraZeneca
Merck
Lynparza
HER-2 negative breast cancer
breast cancer
Rivals multiplying, Pfizer appeals to doctor preferences with Ibrance's latest label win
Fierce Pharma
Tue, 04/4/17 - 10:58 pm
Pfizer
Ibrance
Novartis
Kisqali
Eli Lilly
abemaciclib
HER-2 negative breast cancer
breast cancer